Concerning PV suspected patients, the association of a JAK2 mutation with nearly all the patients with the disease makes the use of red cell mass measurement to individualize PV from ‘secondary’ or ‘apparent’ polycythemia useless. Peripheral blood JAK2V617F screening is thus the preferred first test for evaluating a patient with suspected PV. Because JAK2V617F also occurs in approximately 50% of patients with either ET or PMF, the WHO panel proposes to include mutation screening in the diagnostic work-up of both diseases. These new WHO criteria and the algorithms proposed by Drs Tefferi and Vardiman were published in Leukemia 2008 22: 14-22.
“We are pleased that the WHO, a respected institution promoting, among others, the standardization of disease classification and diagnostic, has rapidly recognized the breakthrough discovery of Dr. Vainchenker that shed light on the pathogenesis of a group of leukemia. This recognition is a further encouragement for Ipsogen to offer standardized assays to the clinical community to ensure the most accurate diagnostic to patients and physicians” said Fabienne Hermitte, Director R&D and Regulatory Affairs at Ipsogen.
About CMPDs According to the new WHO criteria, CMPDs should now be refered to as MPNs (for Myeloproliferative Neoplasms). It is a closely related group of hematological malignancies in which the bone marrow cells that produce the body's blood cells develop and function abnormally. The disorders are progressive blood cancers that can strike anyone at any age, and for which there is no known cure. The three main myeloproliferative disorders are Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Primary Myelofibrosis (PMF). More information about MPDs can be found at http://mpdfoundation.org
About JAK2 MutaScreen™ and JAK2 MutaQuant™ kits Ipsogen has developed both screening and quantification JAK2V617F assays. JAK2 MutaScreen™ kits were designed for the accurate detection and the estimation of the percentage of the mutation, while JAK2 MutaQuant ™ Kit allows precise quantification of JAK2 mutant (V617F) and wild type alleles. These kits are commercially available worldwide as Research Use Only kits under MSPP-01, 02 & 03 and MQPP-01 references respectively. Learn more about JAK2 assays at http://www.ipsogen.com/products/index_mutascreen_tm_jak2.html.
JAK2 V617F mutation and uses thereof are protected by international patent application W02006045827 licensed exclusively worldwide to Ipsogen; US patent pending (US2006/0288432). The purchase of a MutaQuant™ or MutaScreen™ product does not convey any right for its use in clinical diagnostic applications or in the context of patient testing within clinical trials. No patent rights for practising quantitative PCR, such as 5’Nuclease Process, or for using ARMS™ Technology are conveyed expressly, by implication, or by estoppel.
About IPSOGEN IPSOGEN is a molecular diagnostic company focused on the development and commercialization of innovative diagnostic products to guide treatment options in cancers. IPSOGEN has built a comprehensive portfolio of unique products in blood cancers available in over 50 countries all over the world to leading institutions involved in cancer care. IPSOGEN products are registered as IVD in Europe.
Leveraging its expertise in blood cancers, IPSOGEN has developed, in partnership with leading cancer institutions, a pipeline of diagnostic products in breast cancer.
IPSOGEN is headquartered in Marseille, France and has its U.S. offices in New Haven, Connecticut. For more information on IPSOGEN, please visit: http://www.ipsogen.com.
Contacts IPSOGEN Marc Essodaigui, Dr Marketing & Sales – Tel: + 33 4 9619 0634 – essodaigui@ipsogen.com Ipsogen, the Ipsogen Logo, MutaScreen™ and MutaQuant™ are trademarks owned by Ipsogen
